{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:38:36Z","timestamp":1795145916120,"version":"4.10.3"},"reference-count":295,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41573-023-00791-6","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T10:02:43Z","timestamp":1697191363000},"page":"957-975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-7128","authenticated-orcid":false,"given":"Ursula","family":"Theuretzbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-7887","authenticated-orcid":false,"given":"Benjamin","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-0647","authenticated-orcid":false,"given":"Ma\u00eblle","family":"Duffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-473X","authenticated-orcid":false,"given":"Laura J. V.","family":"Piddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"791_CR1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01991-21","volume":"66","author":"MS Butler","year":"2022","unstructured":"Butler, M. S. et al. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob. Agents Chemother. 66, e0199121 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR2","doi-asserted-by":"publisher","first-page":"e02109","DOI":"10.1128\/mBio.02109-17","volume":"9","author":"L Mart\u00ednez-Garc\u00eda","year":"2018","unstructured":"Mart\u00ednez-Garc\u00eda, L., Gonz\u00e1lez-Alba, J. M., Baquero, F., Cant\u00f3n, R. & Gal\u00e1n, J. C. Ceftazidime is the key diversification and selection driver of VIM-type carbapenemases. mBio 9, e02109\u2013e02117 (2018).","journal-title":"mBio"},{"key":"791_CR3","doi-asserted-by":"publisher","first-page":"757833","DOI":"10.3389\/fmicb.2021.757833","volume":"12","author":"F Baquero","year":"2021","unstructured":"Baquero, F. et al. Allogenous selection of mutational collateral resistance: old drugs select for new resistance within antibiotic families. Front. Microbiol. 12, 757833 (2021).","journal-title":"Front. Microbiol."},{"key":"791_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00290-22","volume":"66","author":"F Rajer","year":"2022","unstructured":"Rajer, F., Allander, L., Karlsson, P. A. & Sandegren, L. Evolutionary trajectories toward high-level \u03b2-lactam\/\u03b2-lactamase inhibitor resistance in the presence of multiple \u03b2-lactamases. Antimicrob. Agents Chemother. 66, e0029022 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-021-04397-x","volume":"41","author":"L Poirel","year":"2022","unstructured":"Poirel, L., Sadek, M., Kusaksizoglu, A. & Nordmann, P. Co-resistance to ceftazidime\u2013avibactam and cefiderocol in clinical isolates producing KPC variants. Eur. J. Clin. Microbiol. Infect. Dis. 41, 677\u2013680 (2022).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"791_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1128\/CMR.00030-10","volume":"24","author":"LL Silver","year":"2011","unstructured":"Silver, L. L. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71\u2013109 (2011).","journal-title":"Clin. Microbiol. Rev."},{"key":"791_CR7","doi-asserted-by":"publisher","first-page":"12887","DOI":"10.1073\/pnas.1717160115","volume":"115","author":"SJ Baker","year":"2018","unstructured":"Baker, S. J., Payne, D. J., Rappuoli, R. & De Gregorio, E. Technologies to address antimicrobial resistance. Proc. Natl Acad. Sci. USA 115, 12887\u201312895 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"791_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd2201","volume":"6","author":"DJ Payne","year":"2007","unstructured":"Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29\u201340 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"791_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrd4572","volume":"14","author":"R Tommasi","year":"2015","unstructured":"Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I. & Miller, A. A. ESKAPEing the labyrinth of antibacterial discovery. Nat. Rev. Drug Discov. 14, 529\u2013542 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"791_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2217\/fmb.10.119","volume":"5","author":"H Brotz-Oesterhelt","year":"2010","unstructured":"Brotz-Oesterhelt, H. & Sass, P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol. 5, 1553\u20131579 (2010).","journal-title":"Future Microbiol."},{"key":"791_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrd3975","volume":"12","author":"K Lewis","year":"2013","unstructured":"Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371\u2013387 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"791_CR12","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1021\/acs.accounts.0c00895","volume":"54","author":"KA Mu\u00f1oz","year":"2021","unstructured":"Mu\u00f1oz, K. A. & Hergenrother, P. J. Facilitating compound entry as a means to discover antibiotics for Gram-negative bacteria. Acc. Chem. Res. 54, 1322\u20131333 (2021).","journal-title":"Acc. Chem. Res."},{"key":"791_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s41589-020-00674-6","volume":"16","author":"S Zhao","year":"2020","unstructured":"Zhao, S. et al. Defining new chemical space for drug penetration into Gram-negative bacteria. Nat. Chem. Biol. 16, 1293\u20131302 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"791_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673\u2013685 (2023).","journal-title":"Nature"},{"key":"791_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/nyas.14930","volume":"1519","author":"T Lluka","year":"2023","unstructured":"Lluka, T. & Stokes, J. M. Antibiotic discovery in the artificial intelligence era. Ann. NY Acad. Sci. 1519, 74\u201393 (2023).","journal-title":"Ann. NY Acad. Sci."},{"key":"791_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","volume":"566","author":"J Lyu","year":"2019","unstructured":"Lyu, J. et al. Ultra-large library docking for discovering new chemotypes. Nature 566, 224\u2013229 (2019).","journal-title":"Nature"},{"key":"791_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-958","volume":"15","author":"FM Mobegi","year":"2014","unstructured":"Mobegi, F. M. et al. From microbial gene essentiality to novel antimicrobial drug targets. BMC Genomics 15, 958 (2014).","journal-title":"BMC Genomics"},{"key":"791_CR18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrd2973","volume":"8","author":"P Agarwal","year":"2009","unstructured":"Agarwal, P. & Searls, D. B. Can literature analysis identify innovation drivers in drug discovery? Nat. Rev. Drug Discov. 8, 865 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"791_CR19","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.2174\/138161207782110408","volume":"13","author":"RP Lange","year":"2007","unstructured":"Lange, R. P., Locher, H. H., Wyss, P. C. & Then, R. L. The targets of currently used antibacterial agents: lessons for drug discovery. Curr. Pharm. Des. 13, 3140\u20133154 (2007).","journal-title":"Curr. Pharm. Des."},{"key":"791_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chom.2019.06.004","volume":"26","author":"U Theuretzbacher","year":"2019","unstructured":"Theuretzbacher, U. & Piddock, L. J. V. Non-traditional antibacterial therapeutic options and challenges. Cell Host Microbe 26, 61\u201372 (2019).","journal-title":"Cell Host Microbe"},{"key":"791_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.pt.2007.08.019","volume":"23","author":"JA Frearson","year":"2007","unstructured":"Frearson, J. A., Wyatt, P. G., Gilbert, I. H. & Fairlamb, A. H. Target assessment for antiparasitic drug discovery. Trends Parasitol. 23, 589\u2013595 (2007).","journal-title":"Trends Parasitol."},{"key":"791_CR22","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1128\/AAC.00548-07","volume":"52","author":"K Streker","year":"2008","unstructured":"Streker, K. et al. In vitro and in vivo validation of ligA and tarI as essential targets in Staphylococcus aureus. Antimicrob. Agents Chemother. 52, 4470\u20134474 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nrg.2017.74","volume":"19","author":"G Rancati","year":"2018","unstructured":"Rancati, G., Moffat, J., Typas, A. & Pavelka, N. Emerging and evolving concepts in gene essentiality. Nat. Rev. Genet. 19, 34\u201349 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"791_CR24","doi-asserted-by":"publisher","first-page":"101963","DOI":"10.1016\/j.gde.2022.101963","volume":"76","author":"N Bosch-Guiteras","year":"2022","unstructured":"Bosch-Guiteras, N. & van Leeuwen, J. Exploring conditional gene essentiality through systems genetics approaches in yeast. Curr. Opin. Genet. Dev. 76, 101963 (2022).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"791_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.15698\/mic2015.08.218","volume":"2","author":"Z Zhang","year":"2015","unstructured":"Zhang, Z. & Ren, Q. Why are essential genes essential? \u2013 the essentiality of Saccharomyces genes. Microb. Cell 2, 280\u2013287 (2015).","journal-title":"Microb. Cell"},{"key":"791_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13238-011-1135-x","volume":"3","author":"A Chessher","year":"2012","unstructured":"Chessher, A. Evaluating the suitability of essential genes as targets for antibiotic screening assays using proteomics. Protein Cell 3, 5\u20137 (2012).","journal-title":"Protein Cell"},{"key":"791_CR27","first-page":"1","volume":"19","author":"Editorial.","year":"2017","unstructured":"Editorial. Putting gene essentiality into context. Nat. Rev. Genet. 19, 1 (2017).","journal-title":"Nat. Rev. Genet."},{"key":"791_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.4155\/fmc.15.42","volume":"7","author":"AS Chaudhary","year":"2015","unstructured":"Chaudhary, A. S., Chen, W., Jin, J., Tai, P. C. & Wang, B. SecA: a potential antimicrobial target. Future Med. Chem. 7, 989\u20131007 (2015).","journal-title":"Future Med. Chem."},{"key":"791_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41573-020-0087-3","volume":"20","author":"CH Emmerich","year":"2021","unstructured":"Emmerich, C. H. et al. Improving target assessment in biomedical research: the GOT-IT recommendations. Nat. Rev. Drug Discov. 20, 64\u201381 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"791_CR30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.chembiol.2014.08.020","volume":"21","author":"P Murima","year":"2014","unstructured":"Murima, P., McKinney, J. D. & Pethe, K. Targeting bacterial central metabolism for drug development. Chem. Biol. 21, 1423\u20131432 (2014).","journal-title":"Chem. Biol."},{"key":"791_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acsinfecdis.6b00185","volume":"3","author":"L Hedstrom","year":"2017","unstructured":"Hedstrom, L. The bare essentials of antibiotic target validation. ACS Infect. Dis. 3, 2\u20134 (2017).","journal-title":"ACS Infect. Dis."},{"key":"791_CR32","doi-asserted-by":"publisher","first-page":"fuac005","DOI":"10.1093\/femsre\/fuac005","volume":"46","author":"AM Hogan","year":"2022","unstructured":"Hogan, A. M. & Cardona, S. T. Gradients in gene essentiality reshape antibacterial research. FEMS Microbiol. Rev. 46, fuac005 (2022).","journal-title":"FEMS Microbiol. Rev."},{"key":"791_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002803","volume":"8","author":"T Bergmiller","year":"2012","unstructured":"Bergmiller, T., Ackermann, M. & Silander, O. K. Patterns of evolutionary conservation of essential genes correlate with their compensability. PLoS Genet. 8, e1002803 (2012).","journal-title":"PLoS Genet."},{"key":"791_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.mib.2015.08.006","volume":"27","author":"PM Dunman","year":"2015","unstructured":"Dunman, P. M. & Tomaras, A. P. Translational deficiencies in antibacterial discovery and new screening paradigms. Curr. Opin. Microbiol. 27, 108\u2013113 (2015).","journal-title":"Curr. Opin. Microbiol."},{"key":"791_CR35","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41564-022-01208-7","volume":"7","author":"F Rosconi","year":"2022","unstructured":"Rosconi, F. et al. A bacterial pan-genome makes gene essentiality strain-dependent and evolvable. Nat. Microbiol. 7, 1580\u20131592 (2022).","journal-title":"Nat. Microbiol."},{"key":"791_CR36","doi-asserted-by":"publisher","first-page":"104608","DOI":"10.1016\/j.micpath.2020.104608","volume":"152","author":"H Kaur","year":"2021","unstructured":"Kaur, H., Kalia, M. & Taneja, N. Identification of novel non-homologous drug targets against Acinetobacter baumannii using subtractive genomics and comparative metabolic pathway analysis. Microb. Pathog. 152, 104608 (2021).","journal-title":"Microb. Pathog."},{"key":"791_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.micpath.2018.12.015","volume":"128","author":"R Uddin","year":"2019","unstructured":"Uddin, R., Masood, F., Azam, S. S. & Wadood, A. Identification of putative non-host essential genes and novel drug targets against Acinetobacter baumannii by in silico comparative genome analysis. Microb. Pathog. 128, 28\u201335 (2019).","journal-title":"Microb. Pathog."},{"key":"791_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28916-7","volume":"8","author":"PIP Ramos","year":"2018","unstructured":"Ramos, P. I. P. et al. An integrative, multi-omics approach towards the prioritization of Klebsiella pneumoniae drug targets. Sci. Rep. 8, 10755 (2018).","journal-title":"Sci. Rep."},{"key":"791_CR39","doi-asserted-by":"publisher","first-page":"104245","DOI":"10.1016\/j.micpath.2020.104245","volume":"146","author":"H Rafiq","year":"2020","unstructured":"Rafiq, H. et al. A computational subtractive genome analysis for the characterization of novel drug targets in Klebsiella pneumoniae strain PittNDM01. Microb. Pathog. 146, 104245 (2020).","journal-title":"Microb. Pathog."},{"key":"791_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.compbiolchem.2018.02.017","volume":"74","author":"R Uddin","year":"2018","unstructured":"Uddin, R. & Jamil, F. Prioritization of potential drug targets against P. aeruginosa by core proteomic analysis using computational subtractive genomics and protein\u2013protein interaction network. Comput. Biol. Chem. 74, 115\u2013122 (2018).","journal-title":"Comput. Biol. Chem."},{"key":"791_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261267","volume":"16","author":"E Nazarshodeh","year":"2021","unstructured":"Nazarshodeh, E., Marashi, S. A. & Gharaghani, S. Structural systems pharmacology: a framework for integrating metabolic network and structure-based virtual screening for drug discovery against bacteria. PLoS ONE 16, e0261267 (2021).","journal-title":"PLoS ONE"},{"key":"791_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-195","volume":"11","author":"TM Bakheet","year":"2010","unstructured":"Bakheet, T. M. & Doig, A. J. Properties and identification of antibiotic drug targets. BMC Bioinformatics 11, 195 (2010).","journal-title":"BMC Bioinformatics"},{"key":"791_CR43","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1016\/j.cell.2021.06.033","volume":"184","author":"B Bosch","year":"2021","unstructured":"Bosch, B. et al. Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis. Cell 184, 4579\u20134592.e24 (2021).","journal-title":"Cell"},{"key":"791_CR44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cels.2020.09.009","volume":"11","author":"JS Hawkins","year":"2020","unstructured":"Hawkins, J. S. et al. Mismatch-CRISPRi reveals the co-varying expression\u2013fitness relationships of essential genes in Escherichia coli and Bacillus subtilis. Cell Syst. 11, 523\u2013535.e9 (2020).","journal-title":"Cell Syst."},{"key":"791_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/srep13210","volume":"5","author":"H Luo","year":"2015","unstructured":"Luo, H., Gao, F. & Lin, Y. Evolutionary conservation analysis between the essential and nonessential genes in bacterial genomes. Sci. Rep. 5, 13210 (2015).","journal-title":"Sci. Rep."},{"key":"791_CR46","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/1873-3468.12192","volume":"590","author":"PVPS Arun","year":"2016","unstructured":"Arun, P. V. P. S. et al. Identification and functional analysis of essential, conserved, housekeeping and duplicated genes. FEBS Lett. 590, 1428\u20131437 (2016).","journal-title":"FEBS Lett."},{"key":"791_CR47","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1128\/JB.182.15.4146-4152.2000","volume":"182","author":"W Du","year":"2000","unstructured":"Du, W. et al. Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in Gram-positive bacteria. J. Bacteriol. 182, 4146\u20134152 (2000).","journal-title":"J. Bacteriol."},{"key":"791_CR48","doi-asserted-by":"publisher","first-page":"e3765","DOI":"10.7717\/peerj.3765","volume":"5","author":"S Naz","year":"2017","unstructured":"Naz, S., Ngo, T., Farooq, U. & Abagyan, R. Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens. PeerJ 5, e3765\u2013e3765 (2017).","journal-title":"PeerJ"},{"key":"791_CR49","first-page":"365","volume":"398","author":"P Klahn","year":"2016","unstructured":"Klahn, P. & Bronstrup, M. New structural templates for clinically validated and novel targets in antimicrobial drug research and development. Curr. Top. Microbiol. Immunol. 398, 365\u2013417 (2016).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"791_CR50","doi-asserted-by":"publisher","first-page":"845469","DOI":"10.3389\/fitd.2022.845469","volume":"3","author":"RR Miranda","year":"2022","unstructured":"Miranda, R. R., Parthasarathy, A. & Hudson, A. O. Exploration of chemical biology approaches to facilitate the discovery and development of novel antibiotics. Front. Trop. Dis. 3, 845469 (2022).","journal-title":"Front. Trop. Dis."},{"key":"791_CR51","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1016\/j.bmc.2016.06.044","volume":"24","author":"LL Silver","year":"2016","unstructured":"Silver, L. L. A gestalt approach to Gram-negative entry. Bioorg. Med. Chem. 24, 6379\u20136389 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"791_CR52","doi-asserted-by":"publisher","first-page":"D241","DOI":"10.1093\/nar\/gkq1093","volume":"39","author":"NY Yu","year":"2011","unstructured":"Yu, N. Y., Laird, M. R., Spencer, C. & Brinkman, F. S. PSORTdb \u2014 an expanded, auto-updated, user-friendly protein subcellular localization database for Bacteria and Archaea. Nucleic Acids Res. 39, D241\u2013D244 (2011).","journal-title":"Nucleic Acids Res."},{"key":"791_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00894-020-04385-6","volume":"26","author":"C Agoni","year":"2020","unstructured":"Agoni, C., Olotu, F. A., Ramharack, P. & Soliman, M. E. Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say? J. Mol. Model. 26, 120 (2020).","journal-title":"J. Mol. Model."},{"key":"791_CR54","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.drudis.2018.02.015","volume":"23","author":"S Vukovic","year":"2018","unstructured":"Vukovic, S. & Huggins, D. J. Quantitative metrics for drug-target ligandability. Drug Discov. Today 23, 1258\u20131266 (2018).","journal-title":"Drug Discov. Today"},{"key":"791_CR55","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1021\/ci100312t","volume":"50","author":"RP Sheridan","year":"2010","unstructured":"Sheridan, R. P., Maiorov, V. N., Holloway, M. K., Cornell, W. D. & Gao, Y.-D. Drug-like density: a method of quantifying the \u201cbindability\u201d of a protein target based on a very large set of pockets and drug-like ligands from the protein data bank. J. Chem. Inf. Model. 50, 2029\u20132040 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"791_CR56","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/bib\/bbz122","volume":"21","author":"J Paananen","year":"2020","unstructured":"Paananen, J. & Fortino, V. An omics perspective on drug target discovery platforms. Brief. Bioinform. 21, 1937\u20131953 (2020).","journal-title":"Brief. Bioinform."},{"key":"791_CR57","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/2472555220916168","volume":"25","author":"J Coyle","year":"2020","unstructured":"Coyle, J. & Walser, R. Applied biophysical methods in fragment-based drug discovery. SLAS Discov. 25, 471\u2013490 (2020).","journal-title":"SLAS Discov."},{"key":"791_CR58","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"791_CR59","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.drudis.2020.09.003","volume":"25","author":"P Canning","year":"2020","unstructured":"Canning, P., Birchall, K., Kettleborough, C. A., Merritt, A. & Coombs, P. J. Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials. Drug Discov. Today 25, 2030\u20132037 (2020).","journal-title":"Drug Discov. Today"},{"key":"791_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16081","volume":"8","author":"CA Machutta","year":"2017","unstructured":"Machutta, C. A. et al. Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening. Nat. Commun. 8, 16081 (2017).","journal-title":"Nat. Commun."},{"key":"791_CR61","doi-asserted-by":"crossref","unstructured":"Sutterlin, H. A., Malinverni, J. C., Lee, S. H., Balibar, C. J. & Roemer, T. in Antibacterials Vol.1 (eds Fisher, J. F., Mobashery, S. & Miller, M. J.) 1\u201329 (Springer, 2018).","DOI":"10.1007\/7355_2016_31"},{"key":"791_CR62","doi-asserted-by":"publisher","first-page":"647060","DOI":"10.3389\/fphar.2021.647060","volume":"12","author":"F Serral","year":"2021","unstructured":"Serral, F. et al. From genome to drugs: new approaches in antimicrobial discovery. Front. Pharmacol. 12, 647060 (2021).","journal-title":"Front. Pharmacol."},{"key":"791_CR63","doi-asserted-by":"publisher","first-page":"21127","DOI":"10.1021\/jacs.1c10200","volume":"143","author":"TM Privalsky","year":"2021","unstructured":"Privalsky, T. M. et al. Prospects for antibacterial discovery and development. J. Am. Chem. Soc. 143, 21127\u201321142 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"791_CR64","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.ade2574","volume":"379","author":"Z Lin","year":"2023","unstructured":"Lin, Z. et al. Evolutionary-scale prediction of atomic level protein structure with a language model. Science 379, 1123\u20131130 (2023).","journal-title":"Science"},{"key":"791_CR65","doi-asserted-by":"publisher","unstructured":"Wua, R. et al. High-resolution de novo structure prediction from primary sequence. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.07.21.500999 (2022).","DOI":"10.1101\/2022.07.21.500999"},{"key":"791_CR66","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/biom11071050","volume":"11","author":"JM Su\u00e1rez-Rivero","year":"2021","unstructured":"Su\u00e1rez-Rivero, J. M. et al. Mitochondria and antibiotics: for good or for evil? Biomolecules 11, 1050 (2021).","journal-title":"Biomolecules"},{"key":"791_CR67","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/pharmrev.122.000568","volume":"75","author":"CA Hoogstraten","year":"2023","unstructured":"Hoogstraten, C. A., Lyon, J. J., Smeitink, J. A. M., Russel, F. G. M. & Schirris, T. J. J. Time to change: a systems pharmacology approach to disentangle mechanisms of drug-induced mitochondrial toxicity. Pharmacol. Rev. 75, 463\u2013486 (2023).","journal-title":"Pharmacol. Rev."},{"key":"791_CR68","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","volume":"21","author":"EM Darby","year":"2023","unstructured":"Darby, E. M. et al. Molecular mechanisms of antibiotic resistance revisited. Nat. Rev. Microbiol. 21, 280\u2013295 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"791_CR69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2020.02.056","volume":"181","author":"K Lewis","year":"2020","unstructured":"Lewis, K. The science of antibiotic discovery. Cell 181, 29\u201345 (2020).","journal-title":"Cell"},{"key":"791_CR70","doi-asserted-by":"publisher","first-page":"a030239","DOI":"10.1101\/cshperspect.a030239","volume":"6","author":"LL Silver","year":"2016","unstructured":"Silver, L. L. Appropriate targets for antibacterial drugs. Cold Spring Harb. Perspect. Med. 6, a030239 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"791_CR71","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1128\/AAC.03774-14","volume":"59","author":"K O\u2019Dwyer","year":"2015","unstructured":"O\u2019Dwyer, K. et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob. Agents Chemother. 59, 289\u2013298 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR72","doi-asserted-by":"publisher","first-page":"e01987-17","DOI":"10.1128\/AAC.01987-17","volume":"62","author":"KP Purnapatre","year":"2018","unstructured":"Purnapatre, K. P. et al. In vitro and in vivo activities of DS86760016, a novel leucyl-tRNA synthetase inhibitor for Gram-negative pathogens. Antimicrob. Agents Chemother. 62, e01987-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR73","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1128\/AAC.00484-15","volume":"59","author":"S Min","year":"2015","unstructured":"Min, S. et al. Frequency of spontaneous resistance to peptide deformylase inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 59, 4644\u20134652 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR74","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1128\/AAC.45.4.1058-1064.2001","volume":"45","author":"CM Apfel","year":"2001","unstructured":"Apfel, C. M. et al. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 45, 1058\u20131064 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR75","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","volume":"22","author":"LS Redgrave","year":"2014","unstructured":"Redgrave, L. S., Sutton, S. B., Webber, M. A. & Piddock, L. J. V. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 22, 438\u2013445 (2014).","journal-title":"Trends Microbiol."},{"key":"791_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd2202","volume":"6","author":"LL Silver","year":"2007","unstructured":"Silver, L. L. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discov. 6, 41\u201355 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"791_CR77","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.cell.2020.05.005","volume":"181","author":"JK Martin II","year":"2020","unstructured":"Martin, J. K. II et al. A dual-mechanism antibiotic kills Gram-negative bacteria and avoids drug resistance. Cell 181, 1518\u20131532 e14 (2020).","journal-title":"Cell"},{"key":"791_CR78","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41564-020-0767-0","volume":"5","author":"U Theuretzbacher","year":"2020","unstructured":"Theuretzbacher, U. Dual-mechanism antibiotics. Nat. Microbiol. 5, 984\u2013985 (2020).","journal-title":"Nat. Microbiol."},{"key":"791_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37624-4","volume":"14","author":"DY Liu","year":"2023","unstructured":"Liu, D. Y. et al. Collateral sensitivity profiling in drug-resistant Escherichia coli identifies natural products suppressing cephalosporin resistance. Nat. Commun. 14, 1976 (2023).","journal-title":"Nat. Commun."},{"key":"791_CR80","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41467-019-09507-0","volume":"10","author":"NA Caveney","year":"2019","unstructured":"Caveney, N. A. et al. Structural insight into YcbB-mediated beta-lactam resistance in Escherichia coli. Nat. Commun. 10, 1849 (2019).","journal-title":"Nat. Commun."},{"key":"791_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006258","volume":"14","author":"D Moradigaravand","year":"2018","unstructured":"Moradigaravand, D. et al. Prediction of antibiotic resistance in Escherichia coli from large-scale pan-genome data. PLoS Comput. Biol. 14, e1006258 (2018).","journal-title":"PLoS Comput. Biol."},{"key":"791_CR82","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.14134","volume":"1459","author":"HI Zgurskaya","year":"2020","unstructured":"Zgurskaya, H. I. & Rybenkov, V. V. Permeability barriers of Gram-negative pathogens. Ann. NY Acad. Sci. 1459, 5\u201318 (2020).","journal-title":"Ann. NY Acad. Sci."},{"key":"791_CR83","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.drudis.2021.03.027","volume":"26","author":"SS Walker","year":"2021","unstructured":"Walker, S. S. & Black, T. A. Are outer-membrane targets the solution for MDR Gram-negative bacteria? Drug Discov. Today 26, 2152\u20132158 (2021).","journal-title":"Drug Discov. Today"},{"key":"791_CR84","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1194\/jlr.R800060-JLR200","volume":"50","author":"CR Raetz","year":"2009","unstructured":"Raetz, C. R. et al. Discovery of new biosynthetic pathways: the lipid A story. J. Lipid Res. 50, S103\u2013S108 (2009).","journal-title":"J. Lipid Res."},{"key":"791_CR85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/antibiotics8040163","volume":"8","author":"KM Lehman","year":"2019","unstructured":"Lehman, K. M. & Grabowicz, M. Countering Gram-negative antibiotic resistance: recent progress in disrupting the outer membrane with novel therapeutics. Antibiotics 8, 163 (2019).","journal-title":"Antibiotics"},{"key":"791_CR86","doi-asserted-by":"publisher","first-page":"10340","DOI":"10.1074\/jbc.REV120.011473","volume":"295","author":"JE Horne","year":"2020","unstructured":"Horne, J. E., Brockwell, D. J. & Radford, S. E. Role of the lipid bilayer in outer membrane protein folding in Gram-negative bacteria. J. Biol. Chem. 295, 10340\u201310367 (2020).","journal-title":"J. Biol. Chem."},{"key":"791_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4014\/jmb.1804.03051","volume":"29","author":"U Choi","year":"2019","unstructured":"Choi, U. & Lee, C. R. Antimicrobial agents that inhibit the outer membrane assembly machines of Gram-negative bacteria. J. Microbiol. Biotechnol. 29, 1\u201310 (2019).","journal-title":"J. Microbiol. Biotechnol."},{"key":"791_CR88","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1128\/IAI.00682-10","volume":"79","author":"A Kovacs-Simon","year":"2011","unstructured":"Kovacs-Simon, A., Titball, R. W. & Michell, S. L. Lipoproteins of bacterial pathogens. Infect. Immun. 79, 548\u2013561 (2011).","journal-title":"Infect. Immun."},{"key":"791_CR89","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3389\/fmicb.2020.01252","volume":"11","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Identification of a compound that inhibits the growth of Gram-negative bacteria by blocking BamA\u2013BamD interaction. Front. Microbiol. 11, 1252 (2020).","journal-title":"Front. Microbiol."},{"key":"791_CR90","doi-asserted-by":"publisher","first-page":"e02138-17","DOI":"10.1128\/mBio.02138-17","volume":"9","author":"MGK Ghequire","year":"2018","unstructured":"Ghequire, M. G. K., Swings, T., Michiels, J., Buchanan, S. K. & De Mot, R. Hitting with a BAM: selective killing by lectin-like bacteriocins. mBio 9, e02138-17 (2018).","journal-title":"mBio"},{"key":"791_CR91","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1073\/pnas.1800043115","volume":"115","author":"KM Storek","year":"2018","unstructured":"Storek, K. M. et al. Monoclonal antibody targeting the \u03b2-barrel assembly machine of Escherichia coli is bactericidal. Proc. Natl Acad. Sci. USA 115, 3692\u20133697 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"791_CR92","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fchem.2019.00045","volume":"7","author":"JA Robinson","year":"2019","unstructured":"Robinson, J. A. Folded synthetic peptides and other molecules targeting outer membrane protein complexes in Gram-negative bacteria. Front. Chem. 7, 45 (2019).","journal-title":"Front. Chem."},{"key":"791_CR93","doi-asserted-by":"publisher","first-page":"21748","DOI":"10.1073\/pnas.1912345116","volume":"116","author":"EM Hart","year":"2019","unstructured":"Hart, E. M. et al. A small-molecule inhibitor of BamA impervious to efflux and the outer membrane permeability barrier. Proc. Natl Acad. Sci. USA 116, 21748\u201321757 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"791_CR94","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1021\/acsinfecdis.2c00459","volume":"8","author":"N Wade","year":"2022","unstructured":"Wade, N. et al. Synthesis and structure\u2013activity studies of \u03b2-barrel assembly machine complex inhibitor MRL-494. ACS Infect. Dis. 8, 2242\u20132252 (2022).","journal-title":"ACS Infect. Dis."},{"key":"791_CR95","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-019-1791-1","volume":"576","author":"Y Imai","year":"2019","unstructured":"Imai, Y. et al. A new antibiotic selectively kills Gram-negative pathogens. Nature 576, 459\u2013464 (2019).","journal-title":"Nature"},{"key":"791_CR96","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-021-03455-w","volume":"593","author":"H Kaur","year":"2021","unstructured":"Kaur, H. et al. The antibiotic darobactin mimics a \u03b2-strand to inhibit outer membrane insertase. Nature 593, 125\u2013129 (2021).","journal-title":"Nature"},{"key":"791_CR97","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41564-022-01227-4","volume":"7","author":"RD Miller","year":"2022","unstructured":"Miller, R. D. et al. Computational identification of a systemic antibiotic for Gram-negative bacteria. Nat. Microbiol. 7, 1661\u20131672 (2022).","journal-title":"Nat. Microbiol."},{"key":"791_CR98","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41586-019-1665-6","volume":"576","author":"A Luther","year":"2019","unstructured":"Luther, A. et al. Chimeric peptidomimetic antibiotics against Gram-negative bacteria. Nature 576, 452\u2013458 (2019).","journal-title":"Nature"},{"key":"791_CR99","doi-asserted-by":"publisher","first-page":"11882","DOI":"10.1039\/D1SC02725E","volume":"12","author":"S Gro\u00df","year":"2021","unstructured":"Gro\u00df, S. et al. Improved broad-spectrum antibiotics against Gram-negative pathogens via darobactin biosynthetic pathway engineering. Chem. Sci. 12, 11882\u201311893 (2021).","journal-title":"Chem. Sci."},{"key":"791_CR100","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ymben.2021.04.007","volume":"66","author":"ZG Wuisan","year":"2021","unstructured":"Wuisan, Z. G., Kresna, I. D. M., Bohringer, N., Lewis, K. & Schaberle, T. F. Optimization of heterologous darobactin A expression and identification of the minimal biosynthetic gene cluster. Metab. Eng. 66, 123\u2013136 (2021).","journal-title":"Metab. Eng."},{"key":"791_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202214094","volume":"62","author":"CE Seyfert","year":"2023","unstructured":"Seyfert, C. E. et al. Darobactins exhibiting superior antibiotic activity by cryo-EM structure guided biosynthetic engineering. Angew. Chem. Int. Ed.\u00a062, e202214094 (2023).","journal-title":"Angew. Chem. Int. Ed."},{"key":"791_CR102","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1021\/acsinfecdis.0c00728","volume":"7","author":"M Steenhuis","year":"2021","unstructured":"Steenhuis, M. et al. Combining cell envelope stress reporter assays in a screening approach to identify BAM complex inhibitors. ACS Infect. Dis. 7, 2250\u20132263 (2021).","journal-title":"ACS Infect. Dis."},{"key":"791_CR103","doi-asserted-by":"publisher","first-page":"933153","DOI":"10.3389\/fphys.2022.933153","volume":"13","author":"S Kaushik","year":"2022","unstructured":"Kaushik, S., He, H. & Dalbey, R. E. Bacterial signal peptides \u2013 navigating the journey of proteins. Front. Physiol. 13, 933153 (2022).","journal-title":"Front. Physiol."},{"key":"791_CR104","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.bbamcr.2014.02.004","volume":"1843","author":"CVS Rao","year":"2014","unstructured":"Rao, C. V. S., De Waelheyns, E., Economou, A. & Ann\u00e9, J. Antibiotic targeting of the bacterial secretory pathway. Biochim. Biophys. Acta\u00a01843, 1762\u20131783 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"791_CR105","first-page":"427","volume":"68","author":"P Ambroziak","year":"2021","unstructured":"Ambroziak, P., Rzepka, I. & Skorko-Glonek, J. SecA \u2013 a multidomain and multitask bacterial export protein. Acta Biochim. Pol. 68, 427\u2013436 (2021).","journal-title":"Acta Biochim. Pol."},{"key":"791_CR106","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ja.2015.53","volume":"68","author":"E De Waelheyns","year":"2015","unstructured":"De Waelheyns, E. et al. Identification of small-molecule inhibitors against SecA by structure-based virtual ligand screening. J. Antibiot. 68, 666\u2013673 (2015).","journal-title":"J. Antibiot."},{"key":"791_CR107","doi-asserted-by":"publisher","first-page":"fny145","DOI":"10.1093\/femsle\/fny145","volume":"365","author":"J Jin","year":"2018","unstructured":"Jin, J. et al. SecA inhibitors as potential antimicrobial agents: differential actions on SecA-only and SecA\u2013SecYEG protein-conducting channels. FEMS Microbiol. Lett. 365, fny145 (2018).","journal-title":"FEMS Microbiol. Lett."},{"key":"791_CR108","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1128\/AAC.44.6.1418-1427.2000","volume":"44","author":"LE Alksne","year":"2000","unstructured":"Alksne, L. E. et al. Identification and analysis of bacterial protein secretion inhibitors utilizing a SecA\u2013LacZ reporter fusion system. Antimicrob. Agents Chemother. 44, 1418\u20131427 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81081-2","volume":"11","author":"A-B Seinen","year":"2021","unstructured":"Seinen, A.-B., Spakman, D., van Oijen, A. M. & Driessen, A. J. M. Cellular dynamics of the SecA ATPase at the single molecule level. Sci. Rep. 11, 1433 (2021).","journal-title":"Sci. Rep."},{"key":"791_CR110","doi-asserted-by":"publisher","unstructured":"Braunstein, M., Bensing, B. A. & Sullam, P. M. The two distinct types of SecA2-dependent export systems. Microbiol. Spectr. 7, https:\/\/doi.org\/10.1128\/microspec.PSIB-0025-2018 (2019).","DOI":"10.1128\/microspec.PSIB-0025-2018"},{"key":"791_CR111","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1002\/cmdc.201600421","volume":"11","author":"J Jin","year":"2016","unstructured":"Jin, J. et al. Using chemical probes to assess the feasibility of targeting SecA for developing antimicrobial agents against Gram-negative bacteria. ChemMedChem 11, 2511\u20132521 (2016).","journal-title":"ChemMedChem"},{"key":"791_CR112","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.chembiol.2011.04.007","volume":"18","author":"K Segers","year":"2011","unstructured":"Segers, K. & Ann\u00e9, J. Traffic jam at the bacterial sec translocase: targeting the SecA nanomotor by small-molecule inhibitors. Chem. Biol. 18, 685\u2013698 (2011).","journal-title":"Chem. Biol."},{"key":"791_CR113","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/pro.5560060601","volume":"6","author":"RE Dalbey","year":"1997","unstructured":"Dalbey, R. E., Lively, M. O., Bron, S. & van Dijl, J. M. The chemistry and enzymology of the type I signal peptidases. Protein Sci. 6, 1129\u20131138 (1997).","journal-title":"Protein Sci."},{"key":"791_CR114","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/pro.757","volume":"21","author":"SM Auclair","year":"2012","unstructured":"Auclair, S. M., Bhanu, M. K. & Kendall, D. A. Signal peptidase I: cleaving the way to mature proteins. Protein Sci. 21, 13\u201325 (2012).","journal-title":"Protein Sci."},{"key":"791_CR115","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1093\/jac\/dku309","volume":"69","author":"Y Personne","year":"2014","unstructured":"Personne, Y., Curtis, M. A., Wareham, D. W. & Waite, R. D. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin. J. Antimicrob. Chemother. 69, 3236\u20133243 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"791_CR116","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.bmc.2016.12.003","volume":"25","author":"M De Rosa","year":"2017","unstructured":"De Rosa, M. et al. Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB). Bioorg. Med. Chem. 25, 897\u2013911 (2017).","journal-title":"Bioorg. Med. Chem."},{"key":"791_CR117","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1128\/AAC.00785-12","volume":"56","author":"PA Smith","year":"2012","unstructured":"Smith, P. A. & Romesberg, F. E. Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition. Antimicrob. Agents Chemother. 56, 5054\u20135060 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR118","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1128\/AAC.46.11.3549-3554.2002","volume":"46","author":"MDFS Barbosa","year":"2002","unstructured":"Barbosa, M. D. F. S. et al. Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase i in vitro. Antimicrob. Agents Chemother. 46, 3549\u20133554 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR119","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1016\/j.bmcl.2015.07.072","volume":"25","author":"A Craney","year":"2015","unstructured":"Craney, A. & Romesberg, F. E. The inhibition of type I bacterial signal peptidase: biological consequences and therapeutic potential. Bioorg. Med. Chem. Lett. 25, 4761\u20134766 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"791_CR120","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1128\/AAC.00726-12","volume":"56","author":"AG Therien","year":"2012","unstructured":"Therien, A. G. et al. Broadening the spectrum of beta-lactam antibiotics through inhibition of signal peptidase type I. Antimicrob. Agents Chemother. 56, 4662\u20134670 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR121","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.82885","volume":"11","author":"M Gao","year":"2022","unstructured":"Gao, M., Nakajima, A. D. & Skolnick, J. Deep learning-driven insights into super protein complexes for outer membrane protein biogenesis in bacteria. eLife 11, e82885 (2022).","journal-title":"eLife"},{"key":"791_CR122","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-018-0483-6","volume":"561","author":"PA Smith","year":"2018","unstructured":"Smith, P. A. et al. Optimized arylomycins are a new class of Gram-negative antibiotics. Nature 561, 189\u2013194 (2018).","journal-title":"Nature"},{"key":"791_CR123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021958118","volume":"118","author":"HS Girgis","year":"2021","unstructured":"Girgis, H. S. et al. Single-molecule nanopore sequencing reveals extreme target copy number heterogeneity in arylomycin-resistant mutants. Proc. Natl Acad. Sci. USA 118, e2021958118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"791_CR124","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/biom10020266","volume":"10","author":"BV Bhaskar","year":"2020","unstructured":"Bhaskar, B. V. et al. Structure-based virtual screening of Pseudomonas aeruginosa LpxA inhibitors using pharmacophore-based approach. Biomolecules 10, 266 (2020).","journal-title":"Biomolecules"},{"key":"791_CR125","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1021\/acsinfecdis.1c00650","volume":"8","author":"MD Sacco","year":"2022","unstructured":"Sacco, M. D. et al. Structure-based ligand design targeting Pseudomonas aeruginosa LpxA in lipid A biosynthesis. ACS Infect. Dis. 8, 1231\u20131240 (2022).","journal-title":"ACS Infect. Dis."},{"key":"791_CR126","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1021\/acsinfecdis.9b00127","volume":"6","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Structural and biological basis of small molecule inhibition of Escherichia coli LpxD acyltransferase essential for lipopolysaccharide biosynthesis. ACS Infect. Dis. 6, 1480\u20131489 (2020).","journal-title":"ACS Infect. Dis."},{"key":"791_CR127","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1107\/S1744309112048890","volume":"69","author":"J Badger","year":"2013","unstructured":"Badger, J. et al. Structure determination of LpxD from the lipopolysaccharide-synthesis pathway of Acinetobacter baumannii. Acta Crystallogr. F\u00a069, 6\u20139 (2013).","journal-title":"Acta Crystallogr. F"},{"key":"791_CR128","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1128\/AAC.00140-06","volume":"50","author":"KE Mdluli","year":"2006","unstructured":"Mdluli, K. E. et al. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 2178\u20132184 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR129","doi-asserted-by":"publisher","first-page":"14377","DOI":"10.1021\/acs.jmedchem.1c00888","volume":"64","author":"MD Ryan","year":"2021","unstructured":"Ryan, M. D. et al. Discovery of novel UDP-N-Acetylglucosamine acyltransferase (LpxA) inhibitors with activity against Pseudomonas aeruginosa. J. Med. Chem. 64, 14377\u201314425 (2021).","journal-title":"J. Med. Chem."},{"key":"791_CR130","doi-asserted-by":"publisher","first-page":"ea025304","DOI":"10.1101\/cshperspect.a025304","volume":"6","author":"AL Erwin","year":"2016","unstructured":"Erwin, A. L. Antibacterial drug discovery targeting the lipopolysaccharide biosynthetic enzyme LpxC. Cold Spring Harb. Perspect. Med. 6, ea025304 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"791_CR131","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1021\/acs.accounts.0c00880","volume":"54","author":"P Zhou","year":"2021","unstructured":"Zhou, P. & Hong, J. Structure- and ligand-dynamics-based design of novel antibiotics targeting lipid A enzymes LpxC and LpxH in Gram-negative bacteria. Acc. Chem. Res. 54, 1623\u20131634 (2021).","journal-title":"Acc. Chem. Res."},{"key":"791_CR132","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1021\/acs.jmedchem.9b01605","volume":"63","author":"P Panchaud","year":"2020","unstructured":"Panchaud, P. et al. Optimization of LpxC inhibitor lead compounds focusing on efficacy and formulation for high dose intravenous administration. J. Med. Chem. 63, 88\u2013102 (2020).","journal-title":"J. Med. Chem."},{"key":"791_CR133","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1021\/acs.jmedchem.9b01604","volume":"63","author":"JP Surivet","year":"2020","unstructured":"Surivet, J. P. et al. Discovery of novel inhibitors of LpxC displaying potent in vitro activity against Gram-negative bacteria. J. Med. Chem. 63, 66\u201387 (2020).","journal-title":"J. Med. Chem."},{"key":"791_CR134","doi-asserted-by":"publisher","first-page":"e00977","DOI":"10.1128\/AAC.00977-19","volume":"63","author":"KM Krause","year":"2019","unstructured":"Krause, K. M. et al. Potent LpxC inhibitors with in vitro activity against multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 63, e00977\u2013e01019 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR135","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/cmdc.201900287","volume":"14","author":"F Cohen","year":"2019","unstructured":"Cohen, F. et al. Optimization of LpxC inhibitors for antibacterial activity and cardiovascular safety. ChemMedChem 14, 1560\u20131572 (2019).","journal-title":"ChemMedChem"},{"key":"791_CR136","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12539-018-0299-y","volume":"11","author":"S Ahmad","year":"2019","unstructured":"Ahmad, S. et al. Subtractive genomics, molecular docking and molecular dynamics simulation revealed LpxC as a potential drug target against multi-drug resistant Klebsiella pneumoniae. Interdiscip. Sci. 11, 508\u2013526 (2019).","journal-title":"Interdiscip. Sci."},{"key":"791_CR137","doi-asserted-by":"publisher","first-page":"e01551-14","DOI":"10.1128\/mBio.01551-14","volume":"5","author":"AP Tomaras","year":"2014","unstructured":"Tomaras, A. P. et al. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens. mBio 5, e01551-14 (2014).","journal-title":"mBio"},{"key":"791_CR138","doi-asserted-by":"publisher","first-page":"14805","DOI":"10.1021\/acs.jmedchem.0c01215","volume":"63","author":"Y Yamada","year":"2020","unstructured":"Yamada, Y. et al. Fragment-based discovery of novel non-hydroxamate LpxC inhibitors with antibacterial activity. J. Med. Chem. 63, 14805\u201314820 (2020).","journal-title":"J. Med. Chem."},{"key":"791_CR139","doi-asserted-by":"publisher","first-page":"122960","DOI":"10.1016\/j.ijbiomac.2022.12.179","volume":"234","author":"SK Pal","year":"2023","unstructured":"Pal, S. K. & Kumar, S. LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase) inhibitors: a long path explored for potent drug design. Int. J. Biol. Macromol. 234, 122960 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"791_CR140","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00828-22","volume":"10","author":"I Yoshida","year":"2022","unstructured":"Yoshida, I., Takata, I., Fujita, K., Takashima, H. & Sugiyama, H. TP0586532, a novel non-hydroxamate LpxC inhibitor: potentiating effect on in vitro activity of meropenem against carbapenem-resistant Enterobacteriaceae. Microbiol. Spectr. 10, e0082822 (2022).","journal-title":"Microbiol. Spectr."},{"key":"791_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202200061","volume":"42","author":"M Zoghlami","year":"2023","unstructured":"Zoghlami, M., Oueslati, M., Basharat, Z., Sadfi-Zouaoui, N. & Messaoudi, A. Inhibitor assessment against the LpxC enzyme of antibiotic-resistant Acinetobacter baumannii using virtual screening, dynamics simulation, and in vitro assays. Mol. Inform. 42, e2200061 (2023).","journal-title":"Mol. Inform."},{"key":"791_CR142","doi-asserted-by":"publisher","first-page":"115826","DOI":"10.1016\/j.bmc.2020.115826","volume":"28","author":"T Furuya","year":"2020","unstructured":"Furuya, T. et al. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay. Bioorg. Med. Chem. 28, 115826 (2020).","journal-title":"Bioorg. Med. Chem."},{"key":"791_CR143","doi-asserted-by":"publisher","first-page":"e00312","DOI":"10.1128\/mBio.00312-12","volume":"3","author":"L Lin","year":"2012","unstructured":"Lin, L. et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 3, e00312\u2013e00412 (2012).","journal-title":"mBio"},{"key":"791_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121216","volume":"10","author":"A Emiola","year":"2015","unstructured":"Emiola, A., George, J. & Andrews, S. S. A complete pathway model for lipid a biosynthesis in Escherichia coli. PLoS ONE 10, e0121216 (2015).","journal-title":"PLoS ONE"},{"key":"791_CR145","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1128\/AAC.01490-19","volume":"64","author":"AK Jones","year":"2019","unstructured":"Jones, A. K. et al. Mutations reducing in vitro susceptibility to novel LpxC inhibitors in Pseudomonas aeruginosa and interplay of efflux and nonefflux mechanisms. Antimicrob. Agents Chemother. 64, 17\u201327 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR146","doi-asserted-by":"publisher","first-page":"115326","DOI":"10.1016\/j.ejmech.2023.115326","volume":"253","author":"Z Niu","year":"2023","unstructured":"Niu, Z. et al. Small molecule LpxC inhibitors against Gram-negative bacteria: advances and future perspectives. Eur. J. Med. Chem. 253, 115326 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"791_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51844-z","volume":"9","author":"KG Kroeck","year":"2019","unstructured":"Kroeck, K. G. et al. Discovery of dual-activity small-molecule ligands of Pseudomonas aeruginosa LpxA and LpxD using SPR and X-ray crystallography. Sci. Rep. 9, 15450 (2019).","journal-title":"Sci. Rep."},{"key":"791_CR148","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1021\/jacs.9b13530","volume":"142","author":"W Han","year":"2020","unstructured":"Han, W. et al. Two distinct mechanisms of inhibition of LpxA acyltransferase essential for lipopolysaccharide biosynthesis. J. Am. Chem. Soc. 142, 4445\u20134455 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"791_CR149","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1128\/JB.02552-14","volume":"197","author":"AS Nayar","year":"2015","unstructured":"Nayar, A. S. et al. Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay. J. Bacteriol. 197, 1726\u20131734 (2015).","journal-title":"J. Bacteriol."},{"key":"791_CR150","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300023","volume":"18","author":"SH Kwak","year":"2023","unstructured":"Kwak, S. H. et al. Development of LpxH inhibitors chelating the active site dimanganese metal cluster of LpxH. ChemMedChem 18, e202300023 (2023).","journal-title":"ChemMedChem"},{"key":"791_CR151","doi-asserted-by":"publisher","first-page":"7969","DOI":"10.1074\/jbc.RA118.002503","volume":"293","author":"TE Bohl","year":"2018","unstructured":"Bohl, T. E. et al. The substrate-binding cap of the UDP-diacylglucosamine pyrophosphatase LpxH is highly flexible, enabling facile substrate binding and product release. J. Biol. Chem. 293, 7969\u20137981 (2018).","journal-title":"J. Biol. Chem."},{"key":"791_CR152","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1042\/BST20211030","volume":"49","author":"C Bonifer","year":"2021","unstructured":"Bonifer, C. & Glaubitz, C. MsbA: an ABC transporter paradigm. Biochem. Soc. Trans. 49, 2917\u20132927 (2021).","journal-title":"Biochem. Soc. Trans."},{"key":"791_CR153","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.3390\/ijms22105099","volume":"22","author":"P Gorzelak","year":"2021","unstructured":"Gorzelak, P., Klein, G. & Raina, S. Molecular basis of essentiality of early critical steps in the lipopolysaccharide biogenesis in Escherichia coli K-12: requirement of MsbA, cardiolipin, LpxL, LpxM and GcvB. Int. J. Mol. Sci. 22, 5099 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"791_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6807-9-3","volume":"9","author":"JP Becker","year":"2009","unstructured":"Becker, J. P., Depret, G., Van Bambeke, F., Tulkens, P. M. & Pr\u00e9vost, M. Molecular models of human P-glycoprotein in two different catalytic states. BMC Struct. Biol. 9, 3 (2009).","journal-title":"BMC Struct. Biol."},{"key":"791_CR155","doi-asserted-by":"publisher","first-page":"12466","DOI":"10.1074\/jbc.273.20.12466","volume":"273","author":"Z Zhou","year":"1998","unstructured":"Zhou, Z., White, K. A., Polissi, A., Georgopoulos, C. & Raetz, C. R. H. Function of Escherichia coli MsbA, an essential ABC family transporter, in lipid A and phospholipid biosynthesis. J. Biol. Chem. 273, 12466\u201312475 (1998).","journal-title":"J. Biol. Chem."},{"key":"791_CR156","doi-asserted-by":"publisher","first-page":"26939","DOI":"10.1074\/jbc.M702952200","volume":"282","author":"H Ghanei","year":"2007","unstructured":"Ghanei, H., Abeyrathne, P. D. & Lam, J. S. Biochemical characterization of MsbA from Pseudomonas aeruginosa. J. Biol. Chem. 282, 26939\u201326947 (2007).","journal-title":"J. Biol. Chem."},{"key":"791_CR157","doi-asserted-by":"publisher","first-page":"6834","DOI":"10.1073\/pnas.1804670115","volume":"115","author":"G Zhang","year":"2018","unstructured":"Zhang, G. et al. Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors. Proc. Natl Acad. Sci. USA 115, 6834\u20136839 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"791_CR158","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1021\/acs.jmedchem.1c01909","volume":"65","author":"VA Verma","year":"2022","unstructured":"Verma, V. A. et al. Discovery of inhibitors of the lipopolysaccharide transporter MsbA: from a screening hit to potent wild-type Gram-negative activity. J. Med. Chem. 65, 4085\u20134120 (2022).","journal-title":"J. Med. Chem."},{"key":"791_CR159","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/15476286.2018.1429879","volume":"15","author":"JM Ho","year":"2018","unstructured":"Ho, J. M., Bakkalbasi, E., S\u00f6ll, D. & Miller, C. A. Drugging tRNA aminoacylation. RNA Biol. 15, 667\u2013677 (2018).","journal-title":"RNA Biol."},{"key":"791_CR160","doi-asserted-by":"publisher","first-page":"e01142-18","DOI":"10.1128\/AAC.01142-18","volume":"62","author":"MK Alexander","year":"2018","unstructured":"Alexander, M. K. et al. Disrupting Gram-negative bacterial outer membrane biosynthesis through inhibition of the lipopolysaccharide transporter MsbA. Antimicrob. Agents Chemother. 62, e01142-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR161","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fmicb.2020.00909","volume":"11","author":"ECCM Moura","year":"2020","unstructured":"Moura, E. C. C. M. et al. Thanatin impairs lipopolysaccharide transport complex assembly by targeting LptC\u2013LptA interaction and decreasing LptA stability. Front. Microbiol. 11, 909 (2020).","journal-title":"Front. Microbiol."},{"key":"791_CR162","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41579-019-0201-x","volume":"17","author":"BW Simpson","year":"2019","unstructured":"Simpson, B. W. & Trent, M. S. Pushing the envelope: LPS modifications and their consequences. Nat. Rev. Microbiol. 17, 403\u2013416 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"791_CR163","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.3390\/ijms19092680","volume":"19","author":"G Hicks","year":"2018","unstructured":"Hicks, G. & Jia, Z. Structural basis for the lipopolysaccharide export activity of the bacterial lipopolysaccharide transport system. Int. J. Mol. Sci. 19, 2680 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"791_CR164","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.str.2016.03.026","volume":"24","author":"I Botos","year":"2016","unstructured":"Botos, I. et al. Structural and functional characterization of the LPS transporter LptDE from Gram-negative pathogens. Structure 24, 965\u2013976 (2016).","journal-title":"Structure"},{"key":"791_CR165","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.46258","volume":"8","author":"KM Storek","year":"2019","unstructured":"Storek, K. M. et al. Massive antibody discovery used to probe structure\u2013function relationships of the essential outer membrane protein LptD. eLife 8, e46258 (2019).","journal-title":"eLife"},{"key":"791_CR166","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","volume":"16","author":"I Martin-Loeches","year":"2018","unstructured":"Martin-Loeches, I., Dale, G. E. & Torres, A. Murepavadin: a new antibiotic class in the pipeline. Expert Rev. Anti Infect. Ther. 16, 259\u2013268 (2018).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"791_CR167","doi-asserted-by":"publisher","first-page":"e02355-17","DOI":"10.1128\/AAC.02355-17","volume":"62","author":"A Wach","year":"2018","unstructured":"Wach, A., Dembowsky, K. & Dale, G. E. Pharmacokinetics and safety of intravenous murepavadin infusion in healthy adult subjects administered single and multiple ascending doses. Antimicrob. Agents Chemother. 62, e02355-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR168","doi-asserted-by":"publisher","first-page":"e00511-19","DOI":"10.1128\/AAC.00511-19","volume":"63","author":"KP Romano","year":"2019","unstructured":"Romano, K. P. et al. Mutations in pmrB confer cross-resistance between the LptD inhibitor POL7080 and colistin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 63, e00511-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR169","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/febs.13254","volume":"282","author":"M Bollati","year":"2015","unstructured":"Bollati, M. et al. Crystal structure of LptH, the periplasmic component of the lipopolysaccharide transport machinery from Pseudomonas aeruginosa. FEBS J. 282, 1980\u20131997 (2015).","journal-title":"FEBS J."},{"key":"791_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/srep17593","volume":"5","author":"R Fern\u00e1ndez-Pi\u00f1ar","year":"2015","unstructured":"Fern\u00e1ndez-Pi\u00f1ar, R. et al. In vitro and in vivo screening for novel essential cell-envelope proteins in Pseudomonas aeruginosa. Sci. Rep. 5, 17593 (2015).","journal-title":"Sci. Rep."},{"key":"791_CR171","doi-asserted-by":"publisher","first-page":"183839","DOI":"10.1016\/j.bbamem.2021.183839","volume":"1864","author":"S Sinha","year":"2022","unstructured":"Sinha, S., Dhanabal, V. B., Sperandeo, P., Polissi, A. & Bhattacharjya, S. Linking dual mode of action of host defense antimicrobial peptide thanatin: structures, lipopolysaccharide and LptA(m) binding of designed analogs. Biochim. Biophys. Acta 1864, 183839 (2022).","journal-title":"Biochim. Biophys. Acta"},{"key":"791_CR172","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/antibiotics11101385","volume":"11","author":"X Dai","year":"2022","unstructured":"Dai, X. et al. Identification of a small molecule that inhibits the interaction of LPS transporters LptA and LptC. Antibiotics 11, 1385 (2022).","journal-title":"Antibiotics"},{"key":"791_CR173","doi-asserted-by":"publisher","first-page":"eadg3683","DOI":"10.1126\/sciadv.adg3683","volume":"9","author":"M Schuster","year":"2023","unstructured":"Schuster, M. et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Sci. Adv. 9, eadg3683 (2023).","journal-title":"Sci. Adv."},{"key":"791_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22041522","volume":"22","author":"R Dash","year":"2021","unstructured":"Dash, R. & Bhattacharjya, S. Thanatin: an emerging host defense antimicrobial peptide with multiple modes of action. Int. J. Mol. Sci. 22, 1\u201313 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"791_CR175","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.3390\/molecules28114335","volume":"28","author":"KK Oi","year":"2023","unstructured":"Oi, K. K., Moehle, K., Schuster, M. & Zerbe, O. Early molecular insights into thanatin analogues binding to A. baumannii LptA. Molecules 28, 4335 (2023).","journal-title":"Molecules"},{"key":"791_CR176","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-micro-090816-093754","volume":"71","author":"A Konovalova","year":"2017","unstructured":"Konovalova, A., Kahne, D. E. & Silhavy, T. J. Outer membrane biogenesis. Annu. Rev. Microbiol. 71, 539\u2013556 (2017).","journal-title":"Annu. Rev. Microbiol."},{"key":"791_CR177","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.bbalip.2016.11.009","volume":"1862","author":"SI Narita","year":"2017","unstructured":"Narita, S. I. & Tokuda, H. Bacterial lipoproteins; biogenesis, sorting and quality control. Biochim. Biophys. Acta\u00a01862, 1414\u20131423 (2017).","journal-title":"Biochim. Biophys. Acta"},{"key":"791_CR178","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1073\/pnas.1702248114","volume":"114","author":"M Grabowicz","year":"2017","unstructured":"Grabowicz, M. & Silhavy, T. J. Redefining the essential trafficking pathway for outer membrane lipoproteins. Proc. Natl Acad. Sci. USA 114, 4769\u20134774 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"791_CR179","doi-asserted-by":"publisher","first-page":"e02151-17","DOI":"10.1128\/AAC.02151-17","volume":"62","author":"NN Nickerson","year":"2018","unstructured":"Nickerson, N. N. et al. A novel inhibitor of the LolCDE ABC transporter essential for lipoprotein trafficking in Gram-negative bacteria. Antimicrob. Agents Chemother. 62, e02151-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR180","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1128\/JB.02352-14","volume":"197","author":"SM McLeod","year":"2015","unstructured":"McLeod, S. M. et al. Small-molecule inhibitors of Gram-negative lipoprotein trafficking discovered by phenotypic screening. J. Bacteriol. 197, 1075\u20131082 (2015).","journal-title":"J. Bacteriol."},{"key":"791_CR181","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.drudis.2021.07.016","volume":"26","author":"T Avis","year":"2021","unstructured":"Avis, T., Wilson, F. X., Khan, N., Mason, C. S. & Powell, D. J. Targeted microbiome-sparing antibiotics. Drug Discov. Today 26, 2198\u20132203 (2021).","journal-title":"Drug Discov. Today"},{"key":"791_CR182","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00149-21","volume":"203","author":"J Diao","year":"2021","unstructured":"Diao, J. et al. Inhibition of Escherichia coli lipoprotein diacylglyceryl transferase is insensitive to resistance caused by deletion of Braun\u2019s lipoprotein. J. Bacteriol. 203, e0014921 (2021).","journal-title":"J. Bacteriol."},{"key":"791_CR183","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.aad3747","volume":"351","author":"L Vogeley","year":"2016","unstructured":"Vogeley, L. et al. Structural basis of lipoprotein signal peptidase II action and inhibition by the antibiotic globomycin. Science 351, 876\u2013880 (2016).","journal-title":"Science"},{"key":"791_CR184","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2174\/0929867325666181008143411","volume":"27","author":"J Xia","year":"2020","unstructured":"Xia, J. et al. Bacterial lipoprotein biosynthetic pathway as a potential target for structure-based design of antibacterial agents. Curr. Med. Chem. 27, 1132\u20131150 (2020).","journal-title":"Curr. Med. Chem."},{"key":"791_CR185","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.tibs.2019.03.007","volume":"44","author":"T El Arnaout","year":"2019","unstructured":"El Arnaout, T. & Soulimane, T. Targeting lipoprotein biogenesis: considerations towards antimicrobials. Trends Biochem. Sci. 44, 701\u2013715 (2019).","journal-title":"Trends Biochem. Sci."},{"key":"791_CR186","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.bpj.2022.04.038","volume":"121","author":"TA Caldwell","year":"2022","unstructured":"Caldwell, T. A., Vickery, O. N., Colburn, J. D., Stansfeld, P. J. & Columbus, L. Conformational dynamics of the membrane enzyme LspA upon antibiotic and substrate binding. Biophys. J. 121, 2078\u20132083 (2022).","journal-title":"Biophys. J."},{"key":"791_CR187","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.chembiol.2017.12.011","volume":"25","author":"S Kitamura","year":"2018","unstructured":"Kitamura, S., Owensby, A., Wall, D. & Wolan, D. W. Lipoprotein signal peptidase inhibitors with antibiotic properties identified through design of a robust in vitro HT platform. Cell Chem. Biol. 25, 301\u2013308 e12 (2018).","journal-title":"Cell Chem. Biol."},{"key":"791_CR188","doi-asserted-by":"publisher","first-page":"127419","DOI":"10.1016\/j.bmcl.2020.127419","volume":"30","author":"K Garland","year":"2020","unstructured":"Garland, K. et al. Optimization of globomycin analogs as novel Gram-negative antibiotics. Bioorg. Med. Chem. Lett. 30, 127419 (2020).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"791_CR189","doi-asserted-by":"publisher","first-page":"e02018","DOI":"10.1128\/mBio.02018-20","volume":"11","author":"H Pantua","year":"2020","unstructured":"Pantua, H. et al. Unstable mechanisms of resistance to inhibitors of Escherichia coli lipoprotein signal peptidase. mBio 11, e02018\u2013e02020 (2020).","journal-title":"mBio"},{"key":"791_CR190","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/antibiotics5010012","volume":"5","author":"E Sauvage","year":"2016","unstructured":"Sauvage, E. & Terrak, M. Glycosyltransferases and transpeptidases\/penicillin-binding proteins: valuable targets for new antibacterials. Antibiotics 5, 12 (2016).","journal-title":"Antibiotics"},{"key":"791_CR191","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1039\/c001461n","volume":"27","author":"B Ostash","year":"2010","unstructured":"Ostash, B. & Walker, S. Moenomycin family antibiotics: chemical synthesis, biosynthesis, and biological activity. Nat. Prod. Rep. 27, 1594\u20131617 (2010).","journal-title":"Nat. Prod. Rep."},{"key":"791_CR192","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bioorg.2014.05.007","volume":"55","author":"NF Galley","year":"2014","unstructured":"Galley, N. F., O\u2019Reilly, A. M. & Roper, D. I. Prospects for novel inhibitors of peptidoglycan transglycosylases. Bioorg. Chem. 55, 16\u201326 (2014).","journal-title":"Bioorg. Chem."},{"key":"791_CR193","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bioorg.2014.03.007","volume":"55","author":"T den Blaauwen","year":"2014","unstructured":"den Blaauwen, T., Andreu, J. M. & Monasterio, O. Bacterial cell division proteins as antibiotic targets. Bioorg. Chem. 55, 27\u201338 (2014).","journal-title":"Bioorg. Chem."},{"key":"791_CR194","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/emboj.2011.61","volume":"30","author":"T Mohammadi","year":"2011","unstructured":"Mohammadi, T. et al. Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. EMBO J. 30, 1425\u20131432 (2011).","journal-title":"EMBO J."},{"key":"791_CR195","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.3390\/ijms23073537","volume":"23","author":"M Attaibi","year":"2022","unstructured":"Attaibi, M. & Den Blaauwen, T. An updated model of the divisome: regulation of the septal peptidoglycan synthesis machinery by the divisome. Int. J. Mol. Sci. 23, 3537 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"791_CR196","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202301522","volume":"62","author":"Y Park","year":"2023","unstructured":"Park, Y., Taguchi, A., Baidin, V., Kahne, D. & Walker, S. A time-resolved FRET assay identifies a small molecule that inhibits the essential bacterial cell wall polymerase FtsW. Angew. Chem. Int. Ed.\u00a062, e202301522 (2023).","journal-title":"Angew. Chem. Int. Ed."},{"key":"791_CR197","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.drudis.2018.05.020","volume":"23","author":"J Hering","year":"2018","unstructured":"Hering, J., Dunevall, E., Ek, M. & Br\u00e4nd\u00e9n, G. Structural basis for selective inhibition of antibacterial target MraY, a membrane-bound enzyme involved in peptidoglycan synthesis. Drug Discov. Today 23, 1426\u20131435 (2018).","journal-title":"Drug Discov. Today"},{"key":"791_CR198","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/ph15020134","volume":"15","author":"KT Kubra","year":"2022","unstructured":"Kubra, K. T., Uddin, M. A. & Barabutis, N. Tunicamycin protects against LPS-induced lung injury. Pharmaceuticals 15, 134 (2022).","journal-title":"Pharmaceuticals"},{"key":"791_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35227-z","volume":"13","author":"T Nakaya","year":"2022","unstructured":"Nakaya, T. et al. Synthesis of macrocyclic nucleoside antibacterials and their interactions with MraY. Nat. Commun. 13, 7575 (2022).","journal-title":"Nat. Commun."},{"key":"791_CR200","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nchembio.2270","volume":"13","author":"JK Hakulinen","year":"2017","unstructured":"Hakulinen, J. K. et al. MraY\u2013antibiotic complex reveals details of tunicamycin mode of action. Nat. Chem. Biol. 13, 265\u2013267 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"791_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10957-9","volume":"10","author":"EH Mashalidis","year":"2019","unstructured":"Mashalidis, E. H. et al. Chemical logic of MraY inhibition by antibacterial nucleoside natural products. Nat. Commun. 10, 2917 (2019).","journal-title":"Nat. Commun."},{"key":"791_CR202","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1248\/yakushi.21-00185-2","volume":"142","author":"S Ichikawa","year":"2022","unstructured":"Ichikawa, S. Bridge between total synthesis of bioactive natural products and development of drug leads [Japanese]. Yakugaku Zasshi 142, 355\u2013363 (2022).","journal-title":"Yakugaku Zasshi"},{"key":"791_CR203","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/nyas.12006","volume":"1277","author":"LL Silver","year":"2013","unstructured":"Silver, L. L. Viable screening targets related to the bacterial cell wall. Ann. NY Acad. Sci. 1277, 29\u201353 (2013).","journal-title":"Ann. NY Acad. Sci."},{"key":"791_CR204","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s43141-020-00048-4","volume":"18","author":"GM Amera","year":"2020","unstructured":"Amera, G. M. et al. Prioritization of Mur family drug targets against A. baumannii and identification of their homologous proteins through molecular phylogeny, primary sequence, and structural analysis. J. Genet. Eng. Biotechnol. 18, 33 (2020).","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"791_CR205","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1016\/j.bmc.2018.05.017","volume":"26","author":"H Liang","year":"2018","unstructured":"Liang, H. et al. Elucidating the inhibition of peptidoglycan biosynthesis in Staphylococcus aureus by albocycline, a macrolactone isolated from Streptomyces maizeus. Bioorg. Med. Chem. 26, 3453\u20133460 (2018).","journal-title":"Bioorg. Med. Chem."},{"key":"791_CR206","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1021\/ja510375f","volume":"137","author":"CM Chang","year":"2015","unstructured":"Chang, C. M. et al. Avenaciolides: potential MurA-targeted inhibitors against peptidoglycan biosynthesis in methicillin-resistant Staphylococcus aureus (MRSA). J. Am. Chem. Soc. 137, 267\u2013275 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"791_CR207","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bioorg.2014.03.008","volume":"55","author":"M Hrast","year":"2014","unstructured":"Hrast, M., Sosi\u010d, I., Sink, R. & Gobec, S. Inhibitors of the peptidoglycan biosynthesis enzymes MurA\u2013F. Bioorg. Chem. 55, 2\u201315 (2014).","journal-title":"Bioorg. Chem."},{"key":"791_CR208","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/ph13110362","volume":"13","author":"DJ Hamilton","year":"2020","unstructured":"Hamilton, D. J. et al. Bromo-cyclobutenaminones as new covalent UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) inhibitors. Pharmaceuticals 13, 362 (2020).","journal-title":"Pharmaceuticals"},{"key":"791_CR209","doi-asserted-by":"publisher","first-page":"100137","DOI":"10.1016\/j.crphar.2022.100137","volume":"3","author":"V Gaur","year":"2022","unstructured":"Gaur, V. & Bera, S. Recent developments on UDP-N-acetylmuramoyl-l-alanine-d-gutamate ligase (Mur D) enzyme for antimicrobial drug development: an emphasis on in-silico approaches. Curr. Res. Pharmacol. Drug Discov. 3, 100137 (2022).","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"791_CR210","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/mmi.12758","volume":"94","author":"I Kouidmi","year":"2014","unstructured":"Kouidmi, I., Levesque, R. C. & Paradis-Bleau, C. The biology of Mur ligases as an antibacterial target. Mol. Microbiol. 94, 242\u2013253 (2014).","journal-title":"Mol. Microbiol."},{"key":"791_CR211","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00894-020-04557-4","volume":"26","author":"RK Jha","year":"2020","unstructured":"Jha, R. K. et al. Identification of promising molecules against MurD ligase from Acinetobacter baumannii: insights from comparative protein modelling, virtual screening, molecular dynamics simulations and MM\/PBSA analysis. J. Mol. Model. 26, 304 (2020).","journal-title":"J. Mol. Model."},{"key":"791_CR212","doi-asserted-by":"publisher","first-page":"102922","DOI":"10.1016\/j.arabjc.2020.102922","volume":"14","author":"C Ranjan Sahoo","year":"2021","unstructured":"Ranjan Sahoo, C. et al. Coumarin derivatives as promising antibacterial agent(s). Arab. J. Chem. 14, 102922 (2021).","journal-title":"Arab. J. Chem."},{"key":"791_CR213","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nrd2510","volume":"7","author":"RL Lock","year":"2008","unstructured":"Lock, R. L. & Harry, E. J. Cell-division inhibitors: new insights for future antibiotics. Nat. Rev. Drug Discov. 7, 324\u2013338 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"791_CR214","doi-asserted-by":"publisher","first-page":"14203","DOI":"10.1021\/bi961357b","volume":"35","author":"JM De Pereda","year":"1996","unstructured":"De Pereda, J. M., Leynadier, D., Evangelio, J. A., Chac\u00f3n, P. & Andreu, J. M. Tubulin secondary structure analysis, limited proteolysis sites, and homology to FtsZ. Biochemistry 35, 14203\u201314215 (1996).","journal-title":"Biochemistry"},{"key":"791_CR215","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1128\/JB.181.4.1348-1351.1999","volume":"181","author":"Y Ohashi","year":"1999","unstructured":"Ohashi, Y. et al. The lethal effect of a benzamide derivative, 3-methoxybenzamide, can be suppressed by mutations within a cell division gene, ftsZ, in Bacillus subtilis. J. Bacteriol. 181, 1348\u20131351 (1999).","journal-title":"J. Bacteriol."},{"key":"791_CR216","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004117","volume":"11","author":"A Miguel","year":"2015","unstructured":"Miguel, A. et al. Variations in the binding pocket of an inhibitor of the bacterial division protein FtsZ across genotypes and species. PLoS Comput. Biol. 11, e1004117 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"791_CR217","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1128\/AAC.00708-15","volume":"59","author":"M Kaul","year":"2015","unstructured":"Kaul, M. et al. TXA709, an FtsZ-targeting benzamide prodrug with improved pharmacokinetics and enhanced in vivo efficacy against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 59, 4845\u20134855 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR218","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.bmcl.2013.11.002","volume":"24","author":"NR Stokes","year":"2014","unstructured":"Stokes, N. R. et al. Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ. Bioorg. Med. Chem. Lett. 24, 353\u2013359 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"791_CR219","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1021\/acschembio.7b00323","volume":"12","author":"J Fujita","year":"2017","unstructured":"Fujita, J. et al. Structural flexibility of an inhibitor overcomes drug resistance mutations in Staphylococcus aureus FtsZ. ACS Chem. Biol. 12, 1947\u20131955 (2017).","journal-title":"ACS Chem. Biol."},{"key":"791_CR220","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41429-022-00531-9","volume":"75","author":"JD Rosado-Lugo","year":"2022","unstructured":"Rosado-Lugo, J. D. et al. Evaluation of 2,6-difluoro-3-(oxazol-2-ylmethoxy)benzamide chemotypes as Gram-negative FtsZ inhibitors. J. Antibiot. 75, 385\u2013395 (2022).","journal-title":"J. Antibiot."},{"key":"791_CR221","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3390\/biomedicines10081825","volume":"10","author":"JM Andreu","year":"2022","unstructured":"Andreu, J. M., Huecas, S., Araujo-Bazan, L., Vazquez-Villa, H. & Martin-Fontecha, M. The search for antibacterial inhibitors targeting cell division protein FtsZ at its nucleotide and allosteric binding sites. Biomedicines 10, 1825 (2022).","journal-title":"Biomedicines"},{"key":"791_CR222","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1039\/D1MD00249J","volume":"13","author":"RL Du","year":"2022","unstructured":"Du, R. L. et al. Discovery of FtsZ inhibitors by virtual screening as antibacterial agents and study of the inhibition mechanism. RSC Med. Chem. 13, 79\u201389 (2022).","journal-title":"RSC Med. Chem."},{"key":"791_CR223","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ijbiomac.2022.07.241","volume":"219","author":"F Naz","year":"2022","unstructured":"Naz, F. et al. Screening of plant-based natural compounds as an inhibitor of FtsZ from Salmonella Typhi using the computational, biochemical and in vitro cell-based studies. Int. J. Biol. Macromol. 219, 428\u2013437 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"791_CR224","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008078","volume":"15","author":"JA Slade","year":"2019","unstructured":"Slade, J. A., Brockett, M., Singh, R., Liechti, G. W. & Maurelli, A. T. Fosmidomycin, an inhibitor of isoprenoid synthesis, induces persistence in Chlamydia by inhibiting peptidoglycan assembly. PLoS Pathog. 15, e1008078 (2019).","journal-title":"PLoS Pathog."},{"key":"791_CR225","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197638","volume":"13","author":"S Sanders","year":"2018","unstructured":"Sanders, S. et al. Growth medium-dependent antimicrobial activity of early stage MEP pathway inhibitors. PLoS ONE 13, e0197638 (2018).","journal-title":"PLoS ONE"},{"key":"791_CR226","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1021\/acsinfecdis.7b00176","volume":"4","author":"X Wang","year":"2018","unstructured":"Wang, X. & Dowd, C. S. The methylerythritol phosphate pathway: promising drug targets in the fight against tuberculosis. ACS Infect. Dis. 4, 278\u2013290 (2018).","journal-title":"ACS Infect. Dis."},{"key":"791_CR227","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-020-03074-x","volume":"589","author":"KS Singh","year":"2021","unstructured":"Singh, K. S. et al. IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance. Nature 589, 597\u2013602 (2021).","journal-title":"Nature"},{"key":"791_CR228","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/molecules28031403","volume":"28","author":"A Allamand","year":"2023","unstructured":"Allamand, A., Piechowiak, T., Li\u00e8vremont, D., Rohmer, M. & Grosdemange-Billiard, C. The multifaceted mep pathway: towards new therapeutic perspectives. Molecules 28, 1403 (2023).","journal-title":"Molecules"},{"key":"791_CR229","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/ph15121553","volume":"15","author":"T Knak","year":"2022","unstructured":"Knak, T. et al. Over 40 years of fosmidomycin drug research: a comprehensive review and future opportunities. Pharmaceuticals 15, 1553 (2022).","journal-title":"Pharmaceuticals"},{"key":"791_CR230","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/molecules27030708","volume":"27","author":"H Jobelius","year":"2022","unstructured":"Jobelius, H., Bianchino, G. I., Borel, F., Chaignon, P. & Seemann, M. The reductive dehydroxylation catalyzed by IspH, a source of inspiration for the development of novel anti-infectives. Molecules 27, 708 (2022).","journal-title":"Molecules"},{"key":"791_CR231","doi-asserted-by":"publisher","first-page":"17541","DOI":"10.1074\/jbc.R600004200","volume":"281","author":"YM Zhang","year":"2006","unstructured":"Zhang, Y. M., White, S. W. & Rock, C. O. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem. 281, 17541\u201317544 (2006).","journal-title":"J. Biol. Chem."},{"key":"791_CR232","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/IDR.S25076","volume":"6","author":"AM Allahverdiyev","year":"2013","unstructured":"Allahverdiyev, A. M. et al. The use of platensimycin and platencin to fight antibiotic resistance. Infect. Drug Resist. 6, 99 (2013).","journal-title":"Infect. Drug Resist."},{"key":"791_CR233","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/ph16030425","volume":"16","author":"L Bibens","year":"2023","unstructured":"Bibens, L., Becker, J.-P., Dassonville-Klimpt, A. & Sonnet, P. A review of fatty acid biosynthesis enzyme inhibitors as promising antimicrobial drugs. Pharmaceuticals 16, 425 (2023).","journal-title":"Pharmaceuticals"},{"key":"791_CR234","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/acscentsci.2c00598","volume":"8","author":"EN Parker","year":"2022","unstructured":"Parker, E. N. et al. An iterative approach guides discovery of the FabI inhibitor fabimycin, a late-stage antibiotic candidate with in vivo efficacy against drug-resistant Gram-negative infections. ACS Cent. Sci. 8, 1145\u20131158 (2022).","journal-title":"ACS Cent. Sci."},{"key":"791_CR235","doi-asserted-by":"publisher","first-page":"a027045","DOI":"10.1101\/cshperspect.a027045","volume":"6","author":"J Yao","year":"2016","unstructured":"Yao, J. & Rock, C. O. Resistance mechanisms and the future of bacterial Enoyl-Acyl carrier protein reductase (FabI) antibiotics. Cold Spring Harb. Perspect. Med. 6, a027045 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"791_CR236","doi-asserted-by":"publisher","unstructured":"Leonardi, R. & Jackowski, S. Biosynthesis of pantothenic acid and coenzyme A. EcoSal Plus 2, https:\/\/doi.org\/10.1128\/ecosalplus.3.6.3.4 (2007).","DOI":"10.1128\/ecosalplus.3.6.3.4"},{"key":"791_CR237","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21614-4","volume":"8","author":"LR Chiarelli","year":"2018","unstructured":"Chiarelli, L. R. et al. A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK. Sci. Rep. 8, 3187 (2018).","journal-title":"Sci. Rep."},{"key":"791_CR238","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cmdc.201800652","volume":"14","author":"JA Shapiro","year":"2019","unstructured":"Shapiro, J. A. et al. Identification of specific and nonspecific inhibitors of Bacillus anthracis type III pantothenate kinase (PanK). ChemMedChem 14, 78\u201382 (2019).","journal-title":"ChemMedChem"},{"key":"791_CR239","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1042\/BST20140131","volume":"42","author":"WJ Moolman","year":"2014","unstructured":"Moolman, W. J., de Villiers, M. & Strauss, E. Recent advances in targeting coenzyme A biosynthesis and utilization for antimicrobial drug development. Biochem. Soc. Trans. 42, 1080\u20131086 (2014).","journal-title":"Biochem. Soc. Trans."},{"key":"791_CR240","doi-asserted-by":"publisher","first-page":"8196","DOI":"10.1128\/JB.00732-07","volume":"189","author":"JR Miller","year":"2007","unstructured":"Miller, J. R. et al. Phosphopantetheine adenylyltransferase from Escherichia coli: investigation of the kinetic mechanism and role in regulation of coenzyme A biosynthesis. J. Bacteriol. 189, 8196\u20138205 (2007).","journal-title":"J. Bacteriol."},{"key":"791_CR241","doi-asserted-by":"publisher","first-page":"140566","DOI":"10.1016\/j.bbapap.2020.140566","volume":"1869","author":"A Gupta","year":"2021","unstructured":"Gupta, A., Sharma, P., Singh, T. P. & Sharma, S. Phosphopantetheine adenylyltransferase: a promising drug target to combat antibiotic resistance. Biochim. Biophys. Acta 1869, 140566 (2021).","journal-title":"Biochim. Biophys. Acta"},{"key":"791_CR242","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1128\/AAC.01661-13","volume":"57","author":"BL de Jonge","year":"2013","unstructured":"de Jonge, B. L. et al. Discovery of inhibitors of 4\u2032-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy. Antimicrob. Agents Chemother. 57, 6005\u20136015 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR243","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrm.2016.110","volume":"17","author":"OC Sibon","year":"2016","unstructured":"Sibon, O. C. & Strauss, E. Coenzyme A: to make it or uptake it? Nat. Rev. Mol. Cell Biol. 17, 605\u2013606 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"791_CR244","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1021\/acsinfecdis.7b00214","volume":"4","author":"CM Rath","year":"2018","unstructured":"Rath, C. M. et al. Optimization of CoaD inhibitors against Gram-negative organisms through targeted metabolomics. ACS Infect. Dis. 4, 391\u2013402 (2018).","journal-title":"ACS Infect. Dis."},{"key":"791_CR245","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1021\/acs.jmedchem.7b01861","volume":"61","author":"CK Skepper","year":"2018","unstructured":"Skepper, C. K. et al. Discovery and optimization of phosphopantetheine adenylyltransferase inhibitors with Gram-negative antibacterial activity. J. Med. Chem. 61, 3325\u20133349 (2018).","journal-title":"J. Med. Chem."},{"key":"791_CR246","doi-asserted-by":"publisher","first-page":"10856","DOI":"10.1021\/jacs.0c04427","volume":"142","author":"SE Motika","year":"2020","unstructured":"Motika, S. E. et al. Gram-negative antibiotic active through inhibition of an essential riboswitch. J. Am. Chem. Soc. 142, 10856\u201310862 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"791_CR247","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nature15542","volume":"526","author":"JA Howe","year":"2015","unstructured":"Howe, J. A. et al. Selective small-molecule inhibition of an RNA structural element. Nature 526, 672\u2013677 (2015).","journal-title":"Nature"},{"key":"791_CR248","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1080\/15476286.2016.1216304","volume":"13","author":"JA Howe","year":"2016","unstructured":"Howe, J. A. et al. Atomic resolution mechanistic studies of ribocil: a highly selective unnatural ligand mimic of the E. coli FMN riboswitch. RNA Biol. 13, 946\u2013954 (2016).","journal-title":"RNA Biol."},{"key":"791_CR249","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/antibiotics10010045","volume":"10","author":"V Panchal","year":"2021","unstructured":"Panchal, V. & Brenk, R. Riboswitches as drug targets for antibiotics. Antibiotics 10, 45 (2021).","journal-title":"Antibiotics"},{"key":"791_CR250","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.chembiol.2017.03.014","volume":"24","author":"H Wang","year":"2017","unstructured":"Wang, H. et al. Dual-targeting small-molecule inhibitors of the Staphylococcus aureus FMN riboswitch disrupt riboflavin homeostasis in an infectious setting. Cell Chem. Biol. 24, 576\u2013588.e6 (2017).","journal-title":"Cell Chem. Biol."},{"key":"791_CR251","doi-asserted-by":"publisher","first-page":"fuab003","DOI":"10.1093\/femsre\/fuab003","volume":"45","author":"C Sirithanakorn","year":"2021","unstructured":"Sirithanakorn, C. & Cronan, J. E. Biotin, a universal and essential cofactor: synthesis, ligation and regulation. FEMS Microbiol. Rev. 45, fuab003 (2021).","journal-title":"FEMS Microbiol. Rev."},{"key":"791_CR252","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.chembiol.2014.11.012","volume":"22","author":"SW Park","year":"2015","unstructured":"Park, S. W. et al. Target-based identification of whole-cell active inhibitors of biotin biosynthesis in Mycobacterium tuberculosis. Chem. Biol. 22, 76\u201386 (2015).","journal-title":"Chem. Biol."},{"key":"791_CR253","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/nchembio.1361","volume":"9","author":"S Zlitni","year":"2013","unstructured":"Zlitni, S., Ferruccio, L. F. & Brown, E. D. Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation. Nat. Chem. Biol. 9, 796\u2013804 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"791_CR254","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41564-019-0595-2","volume":"5","author":"LA Carfrae","year":"2020","unstructured":"Carfrae, L. A. et al. Mimicking the human environment in mice reveals that inhibiting biotin biosynthesis is effective against antibiotic-resistant pathogens. Nat. Microbiol. 5, 93\u2013101 (2020).","journal-title":"Nat. Microbiol."},{"key":"791_CR255","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1128\/MMBR.00055-15","volume":"80","author":"C Ma","year":"2016","unstructured":"Ma, C., Yang, X. & Lewis, P. J. Bacterial transcription as a target for antibacterial drug development. Microbiol. Mol. Biol. Rev. 80, 139\u2013160 (2016).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"791_CR256","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1042\/BST20180499","volume":"47","author":"H Mosaei","year":"2019","unstructured":"Mosaei, H. & Harbottle, J. Mechanisms of antibiotics inhibiting bacterial RNA polymerase. Biochem. Soc. Trans. 47, 339\u2013350 (2019).","journal-title":"Biochem. Soc. Trans."},{"key":"791_CR257","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-biophys-070816-033751","volume":"46","author":"E Nogales","year":"2017","unstructured":"Nogales, E., Louder, R. K. & He, Y. Structural insights into the eukaryotic transcription initiation machinery. Annu. Rev. Biophys. 46, 59\u201383 (2017).","journal-title":"Annu. Rev. Biophys."},{"key":"791_CR258","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1128\/AAC.02572-13","volume":"58","author":"F Babakhani","year":"2014","unstructured":"Babakhani, F., Seddon, J. & Sears, P. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile. Antimicrob. Agents Chemother. 58, 2934\u20132937 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"791_CR259","doi-asserted-by":"publisher","first-page":"e02828","DOI":"10.1128\/AEM.02828-17","volume":"84","author":"NM Vior","year":"2018","unstructured":"Vior, N. M. et al. Discovery and biosynthesis of the antibiotic bicyclomycin in distantly related bacterial classes. Appl. Environ. Microbiol. 84, e02828\u201317 (2018).","journal-title":"Appl. Environ. Microbiol."},{"key":"791_CR260","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/wrna.1110","volume":"3","author":"TM Eidem","year":"2012","unstructured":"Eidem, T. M., Roux, C. M. & Dunman, P. M. RNA decay: a novel therapeutic target in bacteria. Wiley Interdiscip. Rev. RNA 3, 443\u2013454 (2012).","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"791_CR261","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrmicro2930","volume":"11","author":"GA Mackie","year":"2013","unstructured":"Mackie, G. A. RNase E: at the interface of bacterial RNA processing and decay. Nat. Rev. Microbiol. 11, 45\u201357 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"791_CR262","doi-asserted-by":"publisher","DOI":"10.1038\/srep08028","volume":"5","author":"L Kime","year":"2015","unstructured":"Kime, L. et al. The first small-molecule inhibitors of members of the ribonuclease E family. Sci. Rep. 5, 8028 (2015).","journal-title":"Sci. Rep."},{"key":"791_CR263","first-page":"100773","volume":"23","author":"CE Mardle","year":"2020","unstructured":"Mardle, C. E. et al. Identification and analysis of novel small molecule inhibitors of RNase E: implications for antibacterial targeting and regulation of RNase E. Biochem. Biophys. Rep. 23, 100773 (2020).","journal-title":"Biochem. Biophys. Rep."},{"key":"791_CR264","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1093\/nar\/gks739","volume":"40","author":"YC Tsai","year":"2012","unstructured":"Tsai, Y. C. et al. Recognition of the 70S ribosome and polysome by the RNA degradosome in Escherichia coli. Nucleic Acids Res. 40, 10417\u201310431 (2012).","journal-title":"Nucleic Acids Res."},{"key":"791_CR265","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ijms23010095","volume":"23","author":"G Prats-Ejarque","year":"2021","unstructured":"Prats-Ejarque, G. et al. Structure-based design of an RNase chimera for antimicrobial therapy. Int. J. Mol. Sci.\/ 23, 95 (2021).","journal-title":"Int. J. Mol. Sci.\/"},{"key":"791_CR266","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ijms16010321","volume":"16","author":"S Chopra","year":"2014","unstructured":"Chopra, S. & Reader, J. tRNAs as antibiotic targets. Int. J. Mol. Sci. 16, 321\u2013349 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"791_CR267","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tim.2020.06.010","volume":"29","author":"V de Cr\u00e9cy-Lagard","year":"2021","unstructured":"de Cr\u00e9cy-Lagard, V. & Jaroch, M. Functions of bacterial tRNA modifications: from ubiquity to diversity. Trends Microbiol. 29, 41\u201353 (2021).","journal-title":"Trends Microbiol."},{"key":"791_CR268","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cels.2019.03.008","volume":"8","author":"I Masuda","year":"2019","unstructured":"Masuda, I. et al. tRNA methylation is a global determinant of bacterial multi-drug resistance. Cell Syst. 8, 302\u2013314.e8 (2019).","journal-title":"Cell Syst."},{"key":"791_CR269","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1021\/acs.jmedchem.9b00582","volume":"62","author":"W Zhong","year":"2019","unstructured":"Zhong, W. et al. Thienopyrimidinone derivatives that inhibit bacterial tRNA (guanine37-N(1))-methyltransferase (TrmD) by restructuring the active site with a tyrosine-flipping mechanism. J. Med. Chem. 62, 7788\u20137805 (2019).","journal-title":"J. Med. Chem."},{"key":"791_CR270","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/biom7010032","volume":"7","author":"S Goto-Ito","year":"2017","unstructured":"Goto-Ito, S., Ito, T. & Yokoyama, S. Trm5 and TrmD: two enzymes from distinct origins catalyze the identical tRNA modification, m(1)G37. Biomolecules 7, 32 (2017).","journal-title":"Biomolecules"},{"key":"791_CR271","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1261\/rna.066746.118","volume":"25","author":"J Jaroensuk","year":"2019","unstructured":"Jaroensuk, J. et al. Crystal structure and catalytic mechanism of the essential m1G37 tRNA methyltransferase TrmD from Pseudomonas aeruginosa. RNA 25, 1481\u20131496 (2019).","journal-title":"RNA"},{"key":"791_CR272","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1021\/acsinfecdis.8b00275","volume":"5","author":"W Zhong","year":"2019","unstructured":"Zhong, W. et al. Targeting the bacterial epitranscriptome for antibiotic development: discovery of novel tRNA-(N1G37) methyltransferase (TrmD) inhibitors. ACS Infect. Dis. 5, 326\u2013335 (2019).","journal-title":"ACS Infect. Dis."},{"key":"791_CR273","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1021\/jm400718n","volume":"56","author":"PJ Hill","year":"2013","unstructured":"Hill, P. J. et al. Selective inhibitors of bacterial t-RNA-(N1G37) methyltransferase (TrmD) that demonstrate novel ordering of the lid domain. J. Med. Chem. 56, 7278\u20137288 (2013).","journal-title":"J. Med. Chem."},{"key":"791_CR274","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3390\/ijms22041750","volume":"22","author":"L Pang","year":"2021","unstructured":"Pang, L., Weeks, S. D. & Van Aerschot, A. Aminoacyl-tRNA synthetases as valuable targets for antimicrobial drug discovery. Int. J. Mol. Sci. 22, 1750 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"791_CR275","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1074\/jbc.REV118.002956","volume":"294","author":"CS Francklyn","year":"2019","unstructured":"Francklyn, C. S. & Mullen, P. Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics. J. Biol. Chem. 294, 5365\u20135385 (2019).","journal-title":"J. Biol. Chem."},{"key":"791_CR276","doi-asserted-by":"publisher","first-page":"5800","DOI":"10.1021\/acs.jmedchem.2c00134","volume":"65","author":"Z Cai","year":"2022","unstructured":"Cai, Z. et al. Design, synthesis, and proof-of-concept of triple-site inhibitors against aminoacyl-tRNA synthetases. J. Med. Chem. 65, 5800\u20135820 (2022).","journal-title":"J. Med. Chem."},{"key":"791_CR277","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3389\/fmicb.2019.02351","volume":"10","author":"KL Harvey","year":"2019","unstructured":"Harvey, K. L., Jarocki, V. M., Charles, I. G. & Djordjevic, S. P. The diverse functional roles of elongation factor Tu (EF-Tu) in microbial pathogenesis. Front. Microbiol. 10, 2351 (2019).","journal-title":"Front. Microbiol."},{"key":"791_CR278","doi-asserted-by":"publisher","first-page":"a025361","DOI":"10.1101\/cshperspect.a025361","volume":"6","author":"S Arenz","year":"2016","unstructured":"Arenz, S. & Wilson, D. N. Bacterial protein synthesis as a target for antibiotic inhibition. Cold Spring Harb. Perspect. Med. 6, a025361 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"791_CR279","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41557-019-0309-7","volume":"11","author":"J Masschelein","year":"2019","unstructured":"Masschelein, J. et al. A dual transacylation mechanism for polyketide synthase chain release in enacyloxin antibiotic biosynthesis. Nat. Chem. 11, 906\u2013912 (2019).","journal-title":"Nat. Chem."},{"key":"791_CR280","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bcp.2016.12.002","volume":"134","author":"FR Fields","year":"2017","unstructured":"Fields, F. R., Lee, S. W. & McConnell, M. J. Using bacterial genomes and essential genes for the development of new antibiotics. Biochem. Pharmacol. 134, 74\u201386 (2017).","journal-title":"Biochem. Pharmacol."},{"key":"791_CR281","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1021\/acs.chemrev.0c01213","volume":"121","author":"JD Prajapati","year":"2021","unstructured":"Prajapati, J. D., Kleinekath\u00f6fer, U. & Winterhalter, M. How to enter a bacterium: bacterial porins and the permeation of antibiotics. Chem. Rev. 121, 5158\u20135192 (2021).","journal-title":"Chem. Rev."},{"key":"791_CR282","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1021\/acsinfecdis.8b00108","volume":"4","author":"S Acosta-Guti\u00e9rrez","year":"2018","unstructured":"Acosta-Guti\u00e9rrez, S. et al. Getting drugs into Gram-negative bacteria: rational rules for permeation through general porins. ACS Infect. Dis. 4, 1487\u20131498 (2018).","journal-title":"ACS Infect. Dis."},{"key":"791_CR283","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1021\/cb5003015","volume":"9","author":"TD Davis","year":"2014","unstructured":"Davis, T. D., Gerry, C. J. & Tan, D. S. General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem. Biol. 9, 2535\u20132544 (2014).","journal-title":"ACS Chem. Biol."},{"key":"791_CR284","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nature22308","volume":"545","author":"MF Richter","year":"2017","unstructured":"Richter, M. F. et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299\u2013304 (2017).","journal-title":"Nature"},{"key":"791_CR285","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/nyas.12803","volume":"1354","author":"MA Farha","year":"2015","unstructured":"Farha, M. A. & Brown, E. D. Unconventional screening approaches for antibiotic discovery. Ann. NY Acad. Sci. 1354, 54\u201366 (2015).","journal-title":"Ann. NY Acad. Sci."},{"key":"791_CR286","doi-asserted-by":"publisher","first-page":"e4444","DOI":"10.1093\/cid\/ciaa859","volume":"73","author":"N Dheman","year":"2021","unstructured":"Dheman, N. et al. An analysis of antibacterial drug development trends in the united states, 1980\u20132019. Clin. Infect. Dis. 73, e4444\u2013e4450 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"791_CR287","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0008125620915289","volume":"62","author":"D Drakeman","year":"2020","unstructured":"Drakeman, D. & Oraiopoulos, N. The risk of de-risking innovation: optimal R&D strategies in ambiguous environments. Calif. Manag. Rev. 62, 42\u201363 (2020).","journal-title":"Calif. Manag. Rev."},{"key":"791_CR288","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cmi.2022.11.027","volume":"29","author":"U Theuretzbacher","year":"2023","unstructured":"Theuretzbacher, U., Baraldi, E., Ciabuschi, F. & Callegari, S. Challenges and shortcomings of antibacterial discovery projects. Clin. Microbiol. Infect. 29, 610\u2013615 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"791_CR289","doi-asserted-by":"publisher","first-page":"eabo7793","DOI":"10.1126\/scitranslmed.abo7793","volume":"14","author":"MA Cook","year":"2022","unstructured":"Cook, M. A. & Wright, G. D. The past, present, and future of antibiotics. Sci. Transl Med. 14, eabo7793 (2022).","journal-title":"Sci. Transl Med."},{"key":"791_CR290","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/17460441.2016.1182484","volume":"11","author":"LH Jones","year":"2016","unstructured":"Jones, L. H. An industry perspective on drug target validation. Expert Opin. Drug Discov. 11, 623\u2013625 (2016).","journal-title":"Expert Opin. Drug Discov."},{"key":"791_CR291","doi-asserted-by":"publisher","first-page":"D787","DOI":"10.1093\/nar\/gkp1014","volume":"38","author":"F Zhu","year":"2010","unstructured":"Zhu, F. et al. Update of TTD: therapeutic target database. Nucleic Acids Res. 38, D787\u2013D791 (2010).","journal-title":"Nucleic Acids Res."},{"key":"791_CR292","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1093\/bioinformatics\/bth300","volume":"20","author":"L Chen","year":"2004","unstructured":"Chen, L., Oughtred, R., Berman, H. M. & Westbrook, J. TargetDB: a target registration database for structural genomics projects. Bioinformatics 20, 2860\u20132862 (2004).","journal-title":"Bioinformatics"},{"key":"791_CR293","doi-asserted-by":"publisher","first-page":"D1118","DOI":"10.1093\/nar\/gkr1053","volume":"40","author":"MP Magarinos","year":"2012","unstructured":"Magarinos, M. P. et al. TDR targets: a chemogenomics resource for neglected diseases. Nucleic Acids Res. 40, D1118\u2013D1127 (2012).","journal-title":"Nucleic Acids Res."},{"key":"791_CR294","doi-asserted-by":"publisher","first-page":"D413","DOI":"10.1093\/nar\/gkx1015","volume":"46","author":"EJ Sosa","year":"2018","unstructured":"Sosa, E. J. et al. Target-Pathogen: a structural bioinformatic approach to prioritize drug targets in pathogens. Nucleic Acids Res. 46, D413\u2013D418 (2018).","journal-title":"Nucleic Acids Res."},{"key":"791_CR295","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-168","volume":"10","author":"V Le Guilloux","year":"2009","unstructured":"Le Guilloux, V., Schmidtke, P. & Tuffery, P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics 10, 168 (2009).","journal-title":"BMC Bioinformatics"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00791-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00791-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00791-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T09:05:12Z","timestamp":1701162312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00791-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":295,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1038\/s41573-023-00791-6","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"15 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}